Form 4 for NVNO enVVeno Medical Corp
Accepted 2021-09-15 00:00:00 ET · period of report 2021-09-13 · accession 0001493152-21-022863 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-15 | 2021-09-13 | NVNO | Jenusaitis Matthew | Dir | M - OptEx | — | +1,042 | 5,884 | +22% | — |
| D | 2021-09-15 | 2021-09-13 | NVNO | Jenusaitis Matthew | Dir | M - OptEx | $0.00 | -1,042 | 2,084 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-13 | M | A | 1,042 | — | 5,884 | D | — | — | (F1) Each restricted stock unit ("RSU") converts into one share of common stock of Hancock Jaffe Laboratories, Inc. |
| 2 | Derivative | Restricted Stock Units | 2021-09-13 | M | D | 1,042 | $0.00 | 2,084 | D | — · — to — | 1,042 Common Stock | (F1) Each restricted stock unit ("RSU") converts into one share of common stock of Hancock Jaffe Laboratories, Inc. (F2) On September 13, 2019, the reporting person was granted 3,125 RSUs (78,125 RSUs pre one-for-twenty five (1:25) reverse stock split that was effected in November 2020), subject to vesting and settlement as described in the person's Form 4, as filed on October 10, 2020. The vesting and settlement of 1,042 RSUs occurred on September 13, 2021 |